Q FEVER DISEASE
===============

An unknown disease was reported in Queensland, Australia in 1933, termed Query Fever (Q fever) that caused non-descript symptoms including fever, headache, and general malaise. The etiological agent, *Coxiella burnetii*, was described in [@B13] and [@B75]. This gram-negative bacterium is an obligate, intracellular pathogen, oscillating between an infectious small cell variant and a replicative large cell variant ([@B45]). *C. burnetii* is a zoonosis, persisting within domesticated ungulates, such as cattle, horses, sheep, and goats ([@B37]; [@B39]).

*Coxiella burnetii* exposure results from contaminated animal byproducts, with human exposure often occurring via inhalation ([@B40]). Infectious particles can travel several kilometers by wind leading to epidemics ([@B69]). Although uncommon relative to inhalational exposure, transmission of the bacteria can occur by ingestion of unpasteurized milk and vectors, specifically ticks ([@B13]; [@B26]). The minimum inoculum of *C. burnetii* is estimated to be 1.18 bacteria with an estimated ID~50~ of 5.58 bacteria, underscoring the potential of this bacterium to cause a significant public health toll ([@B11]).

Many exposed individuals remain asymptomatic, ∼60%; however, those that develop acute Q fever have no distinguishing clinical signs or symptoms and generally present with malaise, fever, headache, chills, and can progress to pneumonia. Acute hepatitis with an elevation of aspartate transaminase and/or alanine transaminase has also been reported ([@B53]). Acute disease is typically self-limiting with low mortality ([@B75]). Contraction of disease during pregnancy, however, can result in complications such as premature birth, stillbirth, and low birth weight due to bacterial tropism for the placenta ([@B14]; [@B66]; [@B28]; [@B38]). All individuals who have been exposed to *C. burnetii* are at risk of developing chronic Q fever ([@B11], [@B12]), with an estimated 1--5% progressing to chronic Q fever, placing them at risk of serious long-term sequelae ([@B10]; [@B47]).

Individuals with pre-existing cardiac valvular disease, aortic aneurysm, vascular grafts, immunocompromised status, and pregnancy at time of exposure are at an increased risk for developing chronic Q fever ([@B56]; [@B18]; [@B36]), which most commonly results in endocarditis or hepatitis ([@B84]). Chronic fatigue syndrome is commonly observed in the short term following diagnosis ([@B12]). The disability adjusted life years burdens were estimated for both H1N1 influenza and Q fever during the recent Netherlands epidemic, with the burden due to chronic Q fever being estimated at 8--28 times more severe per case compared to H1N1 influenza ([@B12]). This highlights the need for better diagnostics and medical countermeasures, particularly in cases of chronic Q fever.

Q FEVER DIAGNOSTICS AND MEDICAL COUNTERMEASURES
===============================================

The current standard for Q fever diagnosis is a commercially available indirect immunofluorescence assay. Cultivation of the organism is not recommended given its high infectivity and requirement of Biosafety Level 3 containment. The limited utility of diagnostic assays for Q fever is exacerbated by the non-specific disease symptoms and lack of clinical indicators to suggest Q fever early in the course of disease. Culture and serum based PCR are only positive in 50--60% of chronically infected individuals ([@B19]). Antibody responses to the Phase I and Phase II antigenic variants allow for the differentiation between acute and chronic phases of disease. Phase I *C. burnetii* possess full-length lipopolysaccharide (LPS) whereas Phase II variants begin to appear in the chronic phase with a truncated LPS lacking O antigen ([@B62]; [@B71]). PCR-based approaches have been explored given that bacterial DNA can be detected prior to the antibody response, thereby curtailing the diagnostic delay. A positive PCR is indicative of infection, but a negative result is inconclusive ([@B20]). The combination of non-descript symptoms and inefficient assays makes the diagnosis of Q fever a fairly daunting challenge.

Although acute Q fever is typically self-limiting, a 2 weeks course of doxycycline is recommended. Chronic Q fever requires a much more intensive antibiotic regimen consisting of 18--24 months of doxycycline and hydroxychloroquine to resolve the infection ([@B30]). A definitive study on the use of prophylactic antibiotic treatment for preventing chronic Q fever has not been undertaken. Although it is suggested for individuals in high risk groups, the benefit and duration of treatment have not been described ([@B29]).

Given the difficulties associated with the treatment of chronic Q fever, vaccinations have been considered a viable alternative for at-risk populations. The utilization of Q-Vax, a formalin-inactivated whole cell vaccine, in Australia is very promising demonstrating that effective, vaccine-mediated protection upward of 5 years against Q fever is possible. ([@B1]). However, Q-Vax does pose issues for individuals who have been previously exposed to *C. burnetii*. Individuals must undergo serology and skin tests prior to vaccination and use is restricted to individuals testing negative for both due to adverse reactions that can occur in previously sensitized individuals ([@B65]). More recent development efforts focused on chemical extraction methods seeking to retain immunogenicity while trying to dampen the adverse reactions. Chloroform-methanol extraction of the Henzerling strain was shown to elicit robust protection but retained the undesirable adverse reactions ([@B80]; [@B81]).

PUBLIC HEALTH AND BIODEFENSE CONCERNS
=====================================

Q fever is a disease of worldwide distribution, but the prevalence varies widely and significant outbreaks do occur on occasion. For example, a large outbreak occurred in the Netherlands from 2007 to 2010, with over 4,000 cases being documented ([@B22]). Seroepidemiology studies have been conducted around the world in both humans and agricultural animals. **Table [1](#T1){ref-type="table"}** provides a synopsis of key studies with respect to the seroprevalence of *C. burnetii* ([@B42]; [@B67]; [@B41]; [@B48]; [@B35]; [@B34]; [@B33]; [@B44]; [@B4]; [@B25]; [@B21]; [@B70]; [@B16]; [@B60]; [@B73]). This synopsis sought to focus on those studies that did not specifically target at-risk individuals such as agricultural workers. Most studies found seroprevalence rates between 3 and 15%. However, a few did suggest rates as high as 20--30%.

###### 

Highlights of seroprevalence of Q fever by nation.

  Nation                      Seroprevalence (%)
  --------------------------- --------------------
  Australia ( [@B70])         5.3^a^
  Australia ( [@B70])         5.0^a^
  Canada ([@B42])             4.1/11.8^b^
  Canada ([@B42])             5.0/14.6^b^
  France ([@B21])             2.1
  Iran ([@B16])               27.8^c^
  Netherlands ([@B73])        4.4
  Netherlands ([@B60])        72.1^d^
  Northern Ireland ([@B44])   12.8
  South Korea ([@B34])        1.5
  Spain (rural) ( [@B67])     15.4
  Spain (urban) ( [@B67])     8.8
  Taiwan ([@B35])             4.2
  Tunisia ([@B41])            26
  Turkey ([@B25])             13.5
  Turkey ([@B33])             32.3
  United States ([@B4])       3.1
  Zambia ([@B48])             8.2

a

Comparisons were made between rural (5.3%) and urban (5.0%) populations

.

b

Percentages reflect seropositivity by complement fixation and microimmunofluorescence assays

.

c

Population was focused on hunters, farmers, health care workers and others who were referred by diagnostic laboratories

.

d

Population was focused on agricultural workers in close association with infected cattle

.

The endemnicity of Q fever in Australia has warranted the use of Q-Vax in vaccination programs. Research into Q fever in Australia has been at least in part driven by economic considerations. Analyses of Q fever from 1991 to 1994 suggested that the costs associated with the disease were over \$1 million Australian dollars and 1,700 weeks of work annually across Australia ([@B23]). While relatively small compared to other diseases, the availability of a low cost, effective vaccine has provided an economic benefit.

Some of the highest rates of prevalence for Q fever have been reported in the Middle East and studies have been conducted in parallel in both human and animal populations. Recent surveys in Iran demonstrated high rates of seropositivity in both humans and sheep. An analysis of sheep showed that 23.7% of animals had antibodies against *C. burnetii* ([@B15]) and parallel studies in human cohorts demonstrated a seropositivity rate of 27.8% which correlated with handling of agricultural animals ([@B16]). Clinical investigation of febrile illnesses of unknown origin in Saudi Arabia showed that out of 51 patients who had febrile illness in the past 4--8 weeks, 35% were seropositive for Q fever compared to just 4% of the control subjects ([@B2]). Similar analyses in an Iranian cohort demonstrated that 24 and 36% of febrile patients were positive for antibody responses against phase I and II antigens, respectively ([@B32]), highlighting the endemnicity of Q fever in the Middle East.

Q fever is a concern for the military due to deployments to regions where the disease is present at relatively high levels. In an analysis of a group of U.S. troops that were deployed to an area of Iraq with known Q fever outbreaks, 7.2% seroconverted during the deployment ([@B58]). A larger study of deployed Warfighters followed a cohort of patients that were admitted to hospitals with fever and other non-specific symptoms. Out of 909 individuals, 88 were seropositive for Q fever ([@B3]). An outbreak among a smaller group of US Marines that were deployed to Iraq resulted in 22/38 developing Q fever ([@B17]). Similar findings have been reported by the United Kingdom military as well. In a 6 months period from May to October, 2008, 26 cases of Helmand Fever were identified in British troops, six of which proved to be Q fever ([@B5]). Thus, while the threat posed by Q fever in the United States is fairly low from a domestic public health perspective, the recent clinical serology data suggest that *C. burnetii* represents a substantial disease burden among the deployed military.

Medical countermeasures against Q fever are of interest from a biodefense perspective. The ease of aerosolization of *C. burnetii*, its low infectious dose, and environmental stability led to its use in offensive programs prior to the Biological Weapons Convention ([@B43]). The United States included *C. burnetii* testing in Operation Whitecoat, wherein conscientious objectors were intentionally exposed and monitored for signs of illness and promptly treated with oxytetracycline ([@B9]). An intentional release was also mimicked by discharging the bacterial aerosol from 3000 feet, or approximately 900 meters ([@B8]). All exposed individuals were treated with antibiotics and followed for development of chronic infection ([@B68]). Testing on *C. burnetii* was also ongoing within the Soviet Union's biological offense program during 1920s through 1990s ([@B55]). The ubiquitous nature of *C. burnetii* in the environment, as well as its history in offensive programs, have spurred interest in vaccine programs. To date, vaccine development efforts have been largely based in empirical studies, partially due to the difficulties associated with culturing and manipulating *C. burnetii*. However, there have been key advances in Q fever biology that can now greatly facilitate the rational design of vaccines.

ADVANCES IN Q FEVER BIOLOGY
===========================

The ability to generate defined mutants of *C. burnetii* and grow the bacterium in cell-free media have provided two major tools that will continue to facilitate Q fever studies ([@B72]). The development of an axenic culture media that support extracellular growth has been crucial to recent advances. The first generation was a complex *Coxiella* medium that allowed protein and ATP synthesis upward of 24 h. Metabolism was retained in a citrate-based buffer supplemented with three complex nutrient sources; neopeptone, fetal bovine serum (FBS), and RPMI cell medium ([@B50]). The second generation medium, Acidified Citrate Cysteine Medium demonstrated bacterial recovery on par with that of Vero cell growth upon the addition of [L]{.smallcaps}-cysteine ([@B51]). The current axenic medium replaced FBS with methyl-β-cyclodextrin. This medium formulation has been used to successfully culture bacteria directly from infected animal tissue homogenate. In addition, the doubling time was decreased, transition between SCV and LCV during stationary phase has been observed, and by adding a soft agar layer facilitates the isolation of pure colonies. ([@B49]; [@B59]). Vero cell extract medium was also found to be permissive to *C. burnetii* growth, with the bacteria retaining its antigenicity profile ([@B64]). Taken together, the advent of cell-free growth media has facilitated the development of new genetic tools to be tested in *C. burnetii* ([@B72]).

The ability to transform Phase II *C. burnetii* was demonstrated by conferring chloramphenicol resistance and mCherry red fluorescent protein by Himar 1 transposon ([@B6]). Twenty clonal isolates of Type IV Secretion System substrate mutants were identified using the same Himar 1 transposon and transposase approach. Screening of these isolates produced 10 that were defective in intracellular replication and vacuole formation, providing insight into the lack of effector redundancy as observed in *Legionella pneumophila* and potential novel virulence factors ([@B78]). Two novel gene deletion systems were developed in *C. burnetii*, a Cre-lox mediated recombination and the loop in-loop out strategy. Using the Cre-lox-mediated recombination, the structural component of type IVB secretion system, dotA, was deleted. A double mutant of dotA and dotB was created with the loop-in/loop-out method in which a suicide plasmid with sacB-mediated counterselection generated an unmarked mutation ([@B7]). Furthermore, saturation of the genome by RNA interference was recently used to create a library of mutants to allow for screening of essential host pathways for successful *C. burnetii* infection ([@B46]). A greater understanding of *C. burnetii* pathogenesis has, and will continue to, drive investigations into the rational design of Q fever vaccines. Recent work has suggested that specific T cell epitopes may be necessary in the successful design of a next-generation vaccine against *C. burnetii* ([@B83]).

PROGRESS TOWARD A Q FEVER VACCINE
=================================

As noted above, Q-Vax has been licensed for use in Australia highlighting an important success by effectively reducing the disease burden as part of a preventative vaccine program. Q fever reporting declined by ∼50% from 2002 to 2006 upon the implementation of a vaccine program targeted toward abattoir workers and farmers ([@B24]). Trials have also been conducted in at-risk older adults in the Netherlands. Although not as promising as immunogenicity data in younger cohorts, patients in this study did demonstrate positive responses by ELISA (46%) and IFN-γ assays (67%) after 6 months and 1 year (60% for both assays; [@B61]). In a related study with a formalin-inactivated vaccine, 13 out of 16 individuals responded to the vaccine with positive measures of antibody titers (titer \> 1:8) and IFN-γ responses (\>31.1 pg of IFN-γ produced; [@B31]).

Although the above trials have provided much hope in terms of an effective Q fever vaccine, there are some issues that remain to be addressed. Protection has clearly been shown in multiple efficacy trials and experiments and a meta-analysis of a range of vaccine campaigns with Henzerling phase I vaccines supported the conclusion that these vaccines do indeed protect against acute disease. However, there were differences when comparing individual studies ([@B52]). Perhaps more importantly, the various forms of inactivated *C. burnetii* vaccines require a pre-sensitivity screening via skin tests and serology. It is important to note that in a recent vaccine campaign in the Netherlands, 22% of individuals had to be excluded from the trial due to positive skin tests and/or serology ([@B27]). From the perspective of developing a vaccine for the biological defense of the U.S. military, the required pre-screening and inability to vaccinate pre-sensitized individuals poses a logistical challenge that warrants investment in a next-generation Q fever vaccine.

Since the development of Q-vax and other related whole-cell inactivated vaccines, the funding for Q fever vaccines, as well as *C. burnetii* in general, has been limited. In terms of next-generation vaccines, the candidate that has moved the furthest along the pathway toward licensure is a chloroform-methanol residue vaccine. This candidate was taken forward into a phase I clinical trial that demonstrated immunogenicity when administered with a primary vaccination and boost 3--6 months later ([@B76]). However, the priming doses did not induce an increase in *C. burnetii*-specific antibody titers and individuals with positive titers were excluded from the study ([@B76]), thus, it is not clear if the chloroform-methanol residue would have the same issue as inactivated vaccines with respect to pre-exposed individuals. The authors of this study discussed ongoing efforts to characterize this vaccine in individuals who were positive for reactions to Q fever via a skin test, but nothing has been published with respect to this to date.

Much of the more recent progress in Q fever has involved a more basic understanding of factors involved in protection against infection as opposed to vaccine development. Phase I LPS has been associated with protection against Q fever in multiple studies ([@B85]; [@B54]). A Phase I LPS-specific monoclonal antibody was shown to be protective in a mouse model of infection ([@B54]). Utilization of a phage display library resulted in the discovery of a peptide mimetic that mimics a protective epitope of Phase I LPS and elicits a protective antibody response in mice ([@B54]). There has been somewhat limited progress toward the identification of protein antigens that may constitute viable antigens to be included in a next-generation Q fever vaccine. Com1 and Mip surface-exposed proteins have been shown to be immunogenic in human clinical samples ([@B74]). Immunization of mice with dendritic cells stimulated with these proteins resulted in increased rates of bacterial clearance, suggesting that the immune response to these proteins may also contribute to protection against disease ([@B82]). Stimulation of T cells with Com1-pulsed monocyte-derived dendritic cells resulted in proliferation and activation of T cells ([@B77]).

Additional insights have also been gained into the type of immune response that may mediate protection against *C. burnetii*. Protection has been associated with antibodies to LPS in past studies ([@B85]; [@B54]), and it has been suggested that although antibodies do contribute to protection, Fc receptors and complement are not required for the mechanism of action ([@B63]). There is also a growing appreciation of the role of T cells in protection against Q fever. Passive transfer of bone marrow-derived dendritic cells stimulated with *C. burnetii* antigens resulted in protection against Q fever. Stimulation with Phase II antigens elicited robust protection, but Com1 and SecB alone elicited partial protection that correlated with CD4^+^ T cell responses ([@B79]). Work in SCID mouse models have shown that CD4^+^ or CD8^+^ T cells were sufficient to provide protection against disease ([@B57]). Vaccine studies utilizing formalin-inactivated *C. burnetii* have shown that T cells are particularly important in vaccine-mediated protection against Q fever ([@B85]).

FUTURE INVESTMENTS IN Q FEVER MEDICAL COUNTERMEASURES
=====================================================

While an effective vaccine is currently in use in Australia, a greater understanding of Q fever may enable the development of a next-generation vaccine with fewer reactogenicity issues. Relative to other Biodefense programs, there can be a much stronger tie between biodefense and public health indications.

Given the relative lack of information regarding protein antigens of *C. burnetii* that may constitute viable protective antigens to be included in vaccine formulation, further investments in antigen discovery for Q fever are warranted. The number of clinical Q fever cases around the world has potential to provide key insights into the discovery phase of a next-generation vaccine. For example, protein microarrays have been used to interrogate the antibody responses in Q fever patients, which covered approximately 93% of the *C. burnetii* proteome and have used this tool to study the immune responses to Q fever infection ([@B74]). Clinical immunology studies would be of continued utility in understanding *C. burnetii* antigens that are immunogenic and may contribute to either protective immune responses or reactogenicity issues associated with vaccinations of previously exposed individuals with whole cell Q fever vaccines.

The ability to tease out protective immune responses versus those involved in reactogenicity will enable rationally designed Q fever vaccines that would not require the requisite pre-screening. In order to develop such a vaccine, the Q fever research community needs the tools to study the immune response to *C. burnetii*. Well-characterized assays will be needed to analyze the immune responses, most likely both antibody and T cell responses, to the antigens being included in next-generation vaccines. If a Q fever vaccine is to be licensed for use, regardless of pre-exposure status, care will need to be taken in animal model experimentation to assess the likelihood of pre-exposure sensitivity.

Concerted efforts to (1) identify optimal antigens to be included in a vaccine, (2) develop models pre-exposure sensitivity to Q fever vaccination, and (3) demonstrate proof-of-concept safety and efficacy against *C. burnetii* challenge could provide candidate countermeasures in the relatively near future. As the community drives toward late-stage vaccine candidates, there will be opportunities for partnerships between the biodefense, public health, and agricultural stakeholders in order to achieve a Q fever vaccine that is relevant to the needs of the broader community as well as the Warfighter.
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